Duramycin
| Duramycin ( Streptoverticillium griseoverticillatum ) | ||
|---|---|---|
|
||
| Rod model of the very similar cinnamycin | ||
| Mass / length primary structure | 19 amino acids | |
| Identifier | ||
| Gene name (s) | PA48009 | |
| External IDs | ||
Duramycin (other name: Moli1901) is a substance that belongs to the polypeptide antibiotics . Duramycin was isolated from the ferment of Streptomyces and Streptoverticilli bacteria strains as early as the 1960s . The structure is composed of 19 amino acids , so it is a nonadecapeptide ( molecular weight = 2012 g / mol). Cinnamycin is a precursor of duramycin with 17 amino acids.
Several studies have looked at the medical utility of this substance. The antimicrobial effectiveness proved to be inferior to other antibiotics. However, duramycin has a number of other physiological effects, including interacting with various membranes in cells and mitochondria . Some of these effects could be possible indications as drug lead.
Duramycin is said to have the ability to open alternative calcium- gated chloride channels in cells of the lung epithelium when inhaled . This is intended to at least partially compensate for a defect in the so-called CFTR channel which is the cause of the lung disease in cystic fibrosis .
A phase 2 study in Germany concluded that the drug was well tolerated when used briefly (inhalation once a day for 5 days) and led to an improvement in lung function (FEV1) of up to 7% even in a small number of patients. In Europe, AOP Orphan Pharmaceuticals AG is involved in this (as of September 2006).
literature
- Hayashi F, Nagashima K, Terui Y, Kawamura Y, Matsumoto K, Itazaki H: The structure of PA48009: the revised structure of duramycin . In: J Antibiot . 43, No. 11, November 1990, pp. 1421-30. PMID 2272918 .
- Grasemann H, Stehling F, Brunar H, et al : Inhalation of Moli1901 in patients with cystic fibrosis . In: Chest . 131, No. 5, May 2007, pp. 1461-6. doi : 10.1378 / chest.06-2085 . PMID 17494794 . , S11 (Lecture 29th ECFS 2006).